These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10921531)

  • 1. Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients.
    Dupuy O; Bauduceau B; Mayaudon H
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):123S-126S. PubMed ID: 10921531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rilmenidine: a clinical overview.
    Reid JL
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):106S-111S. PubMed ID: 10921529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rilmenidine, a selective imidazoline I1 receptor binding ligand, in mild-to-moderate Thai hypertensive patients.
    Buranakitjaroen P; Kittipawong P; Koanantakul B; Piamsomboon C; Prasassarakich N; Silaraks S; Sukonthasarn A; Tiyapant A;
    J Med Assoc Thai; 2003 Oct; 86(10):903-10. PubMed ID: 14650701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity of rilmenidine for I1-imidazoline-binding sites in rabbit proximal tubule cells.
    Gargalidis-Moudanos C; Parini A
    J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S59-62. PubMed ID: 8642808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rilmenidine versus captopril on microalbuminuria: a pilot study in hypertensive type 2 diabetics.
    Bauduceau B; Mayaudon H; Dupuy O
    Cardiovasc Drugs Ther; 1999 Nov; 13(6):547-8. PubMed ID: 10686665
    [No Abstract]   [Full Text] [Related]  

  • 7. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril.
    Bauduceau B; Mayaudon H; Dupuy O
    J Cardiovasc Risk; 2000 Feb; 7(1):57-61. PubMed ID: 10785875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the antihypertensive efficacy of and tolerance to 2 imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy].
    Camilleri G; Portal B; Quiniou G; Clerson P
    Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):169-74. PubMed ID: 12555509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive features of rilmenidine possibly related to its selectivity for imidazoline receptors.
    Harron DW
    Am J Hypertens; 1992 Apr; 5(4 Pt 2):91S-98S. PubMed ID: 1350732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I1 receptors, cardiovascular function, and metabolism.
    Bousquet P
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):317S-321S. PubMed ID: 11721890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on rilmenidine: clinical benefits.
    Reid JL
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):322S-324S. PubMed ID: 11721891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazoline Receptors: A Novel Approach to Hypertension--the Contribution of Rilmenidine. Symposium proceedings. Milan, Italy, June 8, 1993.
    Am J Cardiol; 1994 Dec; 74(13):1A-65A. PubMed ID: 7998579
    [No Abstract]   [Full Text] [Related]  

  • 13. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
    van Zwieten PA
    Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study.
    Meredith PA; Reid JL
    Am J Cardiovasc Drugs; 2004; 4(3):195-200. PubMed ID: 15134471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of pyrrolinic isosteres of rilmenidine. Discovery of cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-amine (LNP 509), an I1 imidazoline receptor selective ligand with hypotensive activity.
    Schann S; Bruban V; Pompermayer K; Feldman J; Pfeiffer B; Renard P; Scalbert E; Bousquet P; Ehrhardt JD
    J Med Chem; 2001 May; 44(10):1588-93. PubMed ID: 11334568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension.
    Yu A; Frishman WH
    J Clin Pharmacol; 1996 Feb; 36(2):98-111. PubMed ID: 8852385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular studies of alpha-2-adrenoceptor and catecholamine-insensitive imidazoline-receptor binding sites using [3H]-rilmenidine in rat brain and kidney.
    King PR; Suzuki S; Nero TL; Gundlach AL; Louis WJ
    J Hypertens Suppl; 1993 Dec; 11(5):S160-1. PubMed ID: 7908962
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of I1 imidazoline receptors in the sympathoinhibition produced by intracisternally administered rilmenidine and moxonidine.
    Szabo B; Urban R
    Arzneimittelforschung; 1997 Sep; 47(9):1009-15. PubMed ID: 9342413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I1 imidazoline receptors in cardiovascular regulation: the place of rilmenidine.
    Head GA; Burke SL
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):89S-98S. PubMed ID: 10921527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.